Comparison of Six-Year Clinical Outcome of Sirolimus- and Paclitaxel-Eluting Stents to Bare-Metal Stents in Patients with ST-Segment Elevation Myocardial Infarction: An Analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus Stent Evaluated at Rotterdam Cardiology Hospital) Registries

Cihan Simsek, Michael Magro, Eric Boersma, Yoshinobu Onuma, S Nauta, Joost Daemen, M Gaspersz, Robert Jan van Geuns, Wim Giessen, Ron van Domburg, PWJC (Patrick) Serruys

Research output: Contribution to journalArticleAcademicpeer-review

15 Citations (Scopus)

Abstract

Background. Short- and long-term data showed that drug-during stents (DES) significantly decreased target vessel revascularization (TVR) and major adverse cardiac event (MACE) rates compared to bare-metal steins (BMS). However, conflicting long-term data remain for patients with ST-segment elevation myocardial infarction (STEMI). Objective. Our aim was to assess the 6-year clinical outcome of all patients undergoing primary percutaneous coronary intervention (PPCI) for a de novo lesion with exclusive use of BMS, sirolimus-eluting scents (SES) and paclitaxel-eluting stents (PES). Methods. Three PPCI cohorts (BMS = 80; SES = 92; PES = 162) were systematically followed for the occurrence of MACE. Results. Very late stent thrombosis was more common after the implantation of SES as compared to PES or BMS (7.6%, 0.6%, and 0.0%, respectively; p = 0.001). Kaplan-Meier estimates indicate no statistically significant difference for mortality between the three scent types at 6 years (BMS = 25%; SES = 15%; PES = 21%; Log-rank p = 0.2). After adjustment for differences in baseline characteristics, mortality, mortality/myocardial infarction (MI), and MACE rates were significantly lower for SES compared to BMS, but not for PES (aHR = 0.41, 95% CI: 0.17-0.98; aHR = 0.44, 95% CI: 0.21-0.96; aHR = 0.35, 95% CI: 0.17-0.72, respectively). No differences were observed between the three stent types for TVR rates. Conclusion. Neither SES nor PES improved safety or efficacy as compared to BMS in a STEMI population at 6 years. After adjusting, the usage of SES resulted in a significant decrease in mortality, mortality/MI and MACE rates as compared to BMS, in contrast to the usage of PES. SES and PES have a similar effectiveness and safety profile, although very late stent thrombosis was more common with SES.
Original languageUndefined/Unknown
Pages (from-to)336-341
Number of pages6
JournalJournal of Invasive Cardiology
Volume23
Issue number8
Publication statusPublished - 2011

Cite this